Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication.

Expert review of clinical pharmacology - 1 Sept 2018

Wang Ling, Wang Shaoming, Qi Juan, Yu Rongguo, Zhuang Jie, Zhuang Boyang, Lou Yongming, Ruan Junshan, Ye Hong, Lin Fangfang

Abstract excerpt

BACKGROUND: Dexmedetomidine is a widely used sedative in clinic, which is mainly metabolized by cytochrome P450 2A6 (CYP2A6). Dexmedetomidine was rarely reported for off-label usage of premedication, but lacking relevant pharmacokinetic investigations. Therefore, our study determined the dexmedetomidine pharmacokinetics of CYP2A6*4 allele in Chinese patients pretreated with dexmedetomidine whose mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2A6

Share to Half-Life

Share to Hypnotics and Sedatives

Share to Mutation

Share to Polymorphism, Genetic

Share to Tissue Distribution

Source

Identifiers

PMID: 30092666
DOI: 10.1080/17512433.2018.1510312

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication.PMID 30092666Read ↗

CYP2A6 genetic variation and dexmedetomidine disposition.Semantic proximity Read ↗

Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.Semantic proximity Read ↗

Distribution of CYP2D6 multiplication, CYP2D6*5, and clinical implications in postoperative patients receiving tramadol analgesia in the Minangkabau ethnic group, IndonesiaSemantic proximity Read ↗

Distribution of CYP2D6 multiplication, CYP2D6*5, and clinical implications in postoperative patients receiving tramadol analgesia in the Minangkabau ethnic group, IndonesiaSemantic proximity Read ↗

Impact of the Cytochrome P450 2B6 (CYP2B6) Gene Polymorphism c.516G>T (rs3745274) on Propofol Dose Variability.Semantic proximity Read ↗

The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia.Semantic proximity Read ↗

Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics.Semantic proximity Read ↗

Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management.Semantic proximity Read ↗

Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine.Semantic proximity Read ↗

The pharmacogenetics of medications used in general anesthesia.Semantic proximity Read ↗

The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.Semantic proximity Read ↗

Challenges in Anesthesia Personalization: Resolving the Pharmacogenomic PuzzleSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.